Navigation Links
Michael D. Farley Appointed Chief Operating Officer of Lupus Foundation of America, Inc.
Date:3/26/2008

WASHINGTON, March 26 /PRNewswire-USNewswire/ -- Michael D. Farley has joined the Lupus Foundation of America, Inc. national office in Washington, DC as the organization's Chief Operating Officer, where he will be responsible for the Foundation's overall organizational administration and field development. Farley has expertise in administering major national voluntary health organizations, including serving most recently as the interim CEO and Chief Community and Corporate Relations Officer for the American Diabetes Association. He also has served as Senior Vice President of Development with the USO World Headquarters, and Vice President for Field Development at the American Red Cross.

Farley will be responsible for the LFA's organization-wide operations and development, including research, public and professional education, internal and external communications, marketing, fund development, strategic partnerships, public policy, field operations, finance, and administration.

Founded more than 30 years ago, the LFA is the foremost national nonprofit voluntary health organization dedicated to finding the causes of and cure for lupus and for providing support, services, and hope to all people affected by lupus. The LFA operates programs of research, education, and advocacy, and has a nationwide network of nearly 300 chapters, branches, and support groups.

In announcing Farley's appointment, LFA President and CEO Sandra C. Raymond cited Farley's extensive expertise in nonprofit administration and field development. "Michael Farley has 25 years of leadership in senior management positions with major national nonprofit organizations," Raymond said. "His experience will be instrumental in helping the LFA meet its critical priorities which are focused on increasing public and private sector support for medical research and expanding support and services to individuals who are affected by lupus."

Farley said this truly is an exciting time to join the Foundation. "New research initiatives hold promise for extraordinary advances in diagnosing and treating lupus. New information is being discovered about the causes of lupus, directly affecting more than 1.5 million Americans. New therapies are ready to emerge that will help manage and control this life-diminishing and life-threatening disease," said Farley. "The LFA is preparing to take advantage of these wonderful advances, and I am honored to do my part in supporting our leadership, scientists, and patient advocates across the country."

Lupus results from an unbalanced immune system that can be destructive to any organ or tissue in the body. Lupus is unpredictable and potentially fatal, yet no satisfactory treatment exists. For more information about lupus and the LFA, go online to lupus.org or call toll free 1-888-38-LUPUS to obtain a free information packet.


'/>"/>
SOURCE Lupus Foundation of America
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Michael Moores SiCKO Becomes the Third Highest Grossing Documentary of All Time Surpassing An Inconvenient Truth
2. Katie Hood Appointed Interim Chief Executive Officer of Michael J. Fox Foundation
3. Clarient Names Michael J. Pellini, M.D. Chief Operating Officer
4. Digital Healthcare Announces Dr. Michael Fleming Joins Executive Team as Medical Director
5. Michael J. Fox Foundation Commits Up to $2 Million for PD Drug Development Under Target Validation 2008
6. BioElectronics Corporation Announces Addition of Michael Seidenman, R.Ph. as Vice President of Sales
7. BioSeek Appoints Michael C. Venuti, Ph.D., Chief Executive Officer
8. Irene Hegeman Richard, MD, Appointed Senior Medical Advisor to The Michael J. Fox Foundation
9. Actress Jenifer Lewis, Authors Dr. Michael Eric Dyson and Susan Taylor Among Featured Speakers for Senator Hughes Behavioral Mental Health Summit
10. Michael J. Fox Foundation Launches Rapid Response Innovation Awards 2008 Following Strong Inaugural Year Response
11. Siemens Medical Solutions Michael Long Recognized as one of Computerworlds 2008 Premier 100 IT Leaders
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/9/2016)... ... , ... "I have gout, and I wanted to treat it naturally," said ... to relieve gout and pain caused by varicose veins. I drank it every morning ... relieved what VA doctors called the worst sinusitis case they'd seen and relieved gas, ...
(Date:12/9/2016)... ... December 09, 2016 , ... The Holy Name Medical Center ... NY, on December 3rd, to benefit Holy Name Medical Center's programs and services. ... raised over $1 million - the largest event in the Center's history, both ...
(Date:12/8/2016)... ... December 08, 2016 , ... ... by the Undersea and Hyperbaric Medical Society (UHMS), the leading authority in hyperbaric ... patient safety. Only a few hospitals and facilities have earned this distinction. This ...
(Date:12/8/2016)... ... December 08, 2016 , ... ... Therapy Management (MTM), adherence, and other pharmacist-delivered patient care services, has announced the ... and Eric Hoessel to vice president of sales. , Litsinger joined Mirixa ...
(Date:12/8/2016)... ... 08, 2016 , ... SunView Software aims to redefine IT ... both engaging and easy to use. Coming off the heels of a successful ... its plans to roll out new AI-powered self-service enhancements to help organizations implement ...
Breaking Medicine News(10 mins):
(Date:12/9/2016)... 9, 2016 Research and Markets has ... report to their offering. ... The report forecasts the global optical transceiver market ... The report covers the present scenario and the ... calculate the market size, the report considers the revenue generated from ...
(Date:12/9/2016)... aTyr Pharma, Inc. (Nasdaq: LIFE ), a biotherapeutics company ... severe, rare diseases, today announced that senior management will participate in ... Conference at the InterContinental Barclay Hotel in New York ... ET. About aTyr Pharma ... aTyr Pharma is engaged in the ...
(Date:12/9/2016)... Bermuda , Dec. 9, 2016  Axovant ... leading clinical-stage biopharmaceutical company focused on the treatment ... the data from a Phase 2b trial evaluating ... care donepezil, compared with donepezil plus placebo in ... that the addition of intepirdine to treatment was ...
Breaking Medicine Technology: